Investor Information

View Corporate Presentation

E-mail Alerts

Enter your e-mail address to receive alerts whenever certain new company information is posted to this site

Savara to Report Third Quarter 2019 Financial Results and Provide Business Update

AUSTIN, Texas--(BUSINESS WIRE)--Oct. 31, 2019-- Savara Inc. (NASDAQ: SVRA), an orphan lung disease company, today announced that the Company will report third quarter 2019 financial results and provide a business update on Thursday, November 7, 2019. Savara management will host a conference call/webcast with an accompanying slide deck at 4:30 p.m. Eastern Time (ET)/1:30 p.m. Pacific Time (PT).

Shareholders and other interested parties may access the call by dialing (855) 239-3120 from the U.S., (855) 669-9657 from Canada, and (412) 542-4127 from elsewhere outside the U.S. and requesting the “Savara Inc.” call. A live webcast of the call can be accessed on the Investors page of Savara’s website at https://www.savarapharma.com/investors/events-presentations/.

Approximately one hour after the call, a telephone replay will be available and will remain available through November 14, 2019 by dialing (877) 344-7529 from the U.S., (855) 669-9658 from Canada and (412) 317-0088 from elsewhere outside the U.S. and entering the replay access code 10135923. A webcast replay will be available on the Investors page of Savara’s website and will remain available for 30 days.

About Savara

Savara is an orphan lung disease company. Savara’s pipeline comprises Molgradex, an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP), in Phase 2a development for nontuberculous mycobacterial (NTM) lung infection in both non-cystic fibrosis (CF) and CF-affected individuals with chronic NTM lung infection; and AeroVanc, a Phase 3-stage inhaled vancomycin for treatment of persistent methicillin-resistant Staphylococcus aureus (MRSA) lung infection in CF. Savara’s strategy involves expanding its pipeline of potentially best-in-class products through indication expansion, strategic development partnerships and product acquisitions, with the goal of becoming a leading company in its field. Savara’s management team has significant experience in orphan drug development and pulmonary medicine, identifying unmet needs, developing and acquiring new product candidates, and effectively advancing them to approvals and commercialization. More information can be found at www.savarapharma.com. (Twitter: @SavaraPharma, LinkedIn: www.linkedin.com/company/savara-pharmaceuticals/)

Source: Savara Inc.

Savara Inc. IR & PR
Anne Erickson (anne.erickson@savarapharma.com)
(512) 851-1366

Back to Top
Savara Nasdaq Opening Bell Ceremony - July 23, 2018
×

We use cookies to give you the best online experience. By agreeing you accept the use of cookies in accordance with our cookie policy.

Privacy Settings saved!
Privacy Settings

When you visit any web site, it may store or retrieve information on your browser, mostly in the form of cookies. Control your personal Cookie Services here.

These cookies allow us to count visits and traffic sources, so we can measure and improve the performance of our site.

We track anonymized user information to improve our website.
  • _ga
  • _gid
  • _gat

Google Analytics works by means of tracking code that is added to the pages of our website. Every user is registered with a unique ID, so that Google Analytics can provide us with insight into how many unique visitors there are to the site, for example, and how many users return. With Google Analytics, we can survey how often any single user has visited the website, what pages they visited, for how long they stayed and how they interacted with the site.
  • __utma
  • __utmt
  • __utmb
  • __utmz
  • __utmv

Decline all Services
Accept all Services